Latest On AMAG Pharmaceuticals, Inc (AMAG):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2020-11-25 11:14 EST | Financials | Company financials have been released. | Neutral |  |
| 2020-11-13 03:10 EST | Earnings Estimate | An EPS average of $0.11 is estimated for the quarter ending on March 31, 2021. | Sell | |
| 2020-11-08 07:07 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-01 16:58 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-09 08:06 EST | Analyst Rating | The Analyst Target Price has increased from $11.43 to $11.96. | Neutral | |
About AMAG Pharmaceuticals, Inc (AMAG):
AMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-inject read more...or device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts. As of November 12, 2020, AMAG Pharmaceuticals, Inc. operates as a subsidiary of Covis Group S.à r.l.
General
- Name AMAG Pharmaceuticals, Inc
- Symbol AMAG
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 440
- Last Split Factor3:2
- Last Split Date1991-09-26
- Fiscal Year EndDecember
- IPO Date1986-06-12
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.amagpharma.com
Valuation
- Forward PE 30.58
- Price/Sales (Trailing 12 Mt.) 1.56
- Price/Book (Most Recent Quarter) 1.87
- Enterprise Value Revenue 2.06
Financials
- Most Recent Quarter 2020-09-30
- Current Year EPS Estimate -$0.63
- Next Year EPS Estimate $0.38
- Next Quarter EPS Estimate $0.05
- Profit Margin -77%
- Operating Margin -14%
- Return on Assets -3%
- Revenue 300.12 million
- Earnings Per Share -$6.83
- Revenue Per Share $8.77
- Gross Profit 219.35 million
- Quarterly Earnings Growth 11.1%
Highlights
- Market Capitalization 477.47 million
- EBITDA -55406000
- PEG Ratio 0.32
- Analyst Target Price $11.96
- Book Value Per Share $7.42
Share Statistics
- Shares Outstanding 34.73 million
- Shares Float 23.47 million
- % Held by Insiders 229%
- % Held by Institutions 101.08%
- Shares Short 6.29 million
- Shares Short Prior Month 7.23 million
- Short Ratio 1.83
- Short % of Float 38%
- Short % of Shares Outstanding 18%
Technicals
- Beta 0.87
- 52 Week High $13.77
- 52 Week Low $4.41
- 50 Day Moving Average 13.65
- 200 Day Moving Average 10.05
Dividends
- Dividend Date N/A
- ExDividend Date N/A
AMAG Pharmaceuticals, Inc (AMAG) Dividend Calendar:
AMAG Pharmaceuticals, Inc (AMAG) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
AMAG Pharmaceuticals, Inc (AMAG) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
AMAG Pharmaceuticals, Inc (AMAG) Chart:
AMAG Pharmaceuticals, Inc (AMAG) News:
Below you will find a list of latest news for AMAG Pharmaceuticals, Inc (AMAG) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
AMAG Pharmaceuticals, Inc (AMAG) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
AMAG Pharmaceuticals, Inc (AMAG) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-06 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-06 | SC 14D9/A (Solicitation, recommendation statements) | |
| 2020-10-26 | SC TO-T/A (Tender offer statement by Third Party) | |
| 2020-10-26 | SC 14D9/A (Solicitation, recommendation statements) | |
| 2020-10-15 | SC 14D9 (Solicitation, recommendation statements) | |
| 2020-10-15 | SC TO-T (Tender offer statement by Third Party) | |
| 2020-10-13 | SC TO-C (Written communication relating to an issuer or third party) | |
| 2020-10-13 | SC 13D (General statement of acquisition of beneficial ownership) | |
| 2020-10-13 | SC14D9C (Written communication relating to third party tender offer) | |
| 2020-10-07 | SC 13G/A (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-10-06 | 8-K (Current report) | |
| 2020-10-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-01 | SC TO-C (Written communication relating to an issuer or third party) | |
| 2020-10-01 | 8-K (Current report) | |
| 2020-10-01 | SC14D9C (Written communication relating to third party tender offer) | |
| 2020-10-01 | SC14D9C (Written communication relating to third party tender offer) | |
| 2020-09-15 | 10-K/A (Annual report [Section 13 and 15(d), not S-K Item 405]) | |
| 2020-09-15 | S-8 (Securities to be offered to employees in employee benefit plans) | |
| 2020-09-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-17 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
AMAG Pharmaceuticals, Inc (AMAG) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of AMAG Pharmaceuticals, Inc (AMAG). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 229%
Institutional Ownership: 10108%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-10-01 | Capital Management LP Camber | 10% Share Holder | Sell | 4,390,000.00 | 13.57 | 59,586,787.00 | 0.00 | |
| 2020-06-02 | DAVID EDWARD JOHNSON | Director | Buy | 10,269.00 | 14,676.00 | | ||
| 2020-06-02 | PAUL R. FONTEYNE | Director | Buy | 10,269.00 | 14,676.00 | | ||
| 2020-06-02 | Anne M. Phillips | Director | Buy | 10,269.00 | 18,949.00 | | ||
| 2020-06-02 | Kathrine O'Brien | Director | Buy | 10,269.00 | 18,949.00 | | ||
| 2020-06-02 | JAMES R SULAT | Director | Buy | 10,269.00 | 35,090.00 | | ||
| 2020-06-02 | John A. Fallon | Director | Buy | 10,269.00 | 37,362.00 | | ||
| 2020-06-02 | GINO SANTINI | Director | Buy | 10,269.00 | 41,473.00 | | ||
| 2020-06-02 | DAVEY SCOON | Director | Buy | 10,269.00 | 43,898.00 | | ||
| 2020-03-16 | ARMISTICE CAPITAL, LLC | 10% Share Holder | Buy | 24,000.00 | 4.87 | 116,880.00 | 348,000.00 | |
| 2020-03-10 | Kelly Schick | Chief Human Resources Officer | Buy | 13,000.00 | 28,234.00 | | ||
| 2020-03-10 | Anthony Casciano | Chief Commercial Officer | Buy | 25,000.00 | 78,209.00 | | ||
| 2020-03-10 | Joseph Vittiglio | CBO, General Counsel | Buy | 25,000.00 | 92,244.00 | | ||
| 2020-03-10 | Edward H Myles | COO & CFO | Buy | 30,000.00 | 98,659.00 | | ||
| 2020-02-25 | ARMISTICE CAPITAL, LLC | 10% Share Holder | Buy | 24,000.00 | 8.29 | 198,960.00 | 312,000.00 | |
| 2020-02-25 | ARMISTICE CAPITAL, LLC | 10% Share Holder | Buy | 12,000.00 | 8.29 | 99,480.00 | 324,000.00 | |
| 2020-01-27 | ARMISTICE CAPITAL, LLC | 10% Share Holder | Buy | 8,000.00 | 9.41 | 75,280.00 | 288,000.00 | |
| 2020-01-27 | ARMISTICE CAPITAL, LLC | 10% Share Holder | Buy | 0.00 | 4,120,000.00 | | ||
| 2020-01-27 | ARMISTICE CAPITAL, LLC | 10% Share Holder | Buy | 8,000.00 | 9.43 | 75,440.00 | 4,120,000.00 | |
| 2020-01-24 | ARMISTICE CAPITAL, LLC | 10% Share Holder | Buy | 40,000.00 | 9.72 | 388,800.00 | 280,000.00 | |